Ibex

Israel-based Ibex Medical Analytics is an AI-driven cancer diagnostics company helping physicians and healthcare professionals diagnose cancer in biopsies through its AI platform, Galen.

The company has deployed its cancer detection solutions, Galen Prostate and Galen Breast, which it claims are routinely used by pathologists to detect hard-to-diagnose cancers. The company is also partnering with drug manufacturers to develop AI-markers that can accelerate oncology drug development. Ibex combines data from digitized glass slides and electronic medical records with AI tools to find insights that can advance pathology and oncology research.

Key customers and partnerships

Ibex is currently focused on growing its customer base in North America and Europe. The company’s diagnostic solutions are deployed at Medipath, France-based private pathology labs, Maccabi’s Pathology Institute, Israel’s largest pathology lab, LDPath, a leading provider of digital pathology services to the National Health Service (NHS) in the UK, among others.

The company entered into partnership with many pharmaceutical companies, including; Indica Labs (May 2021) to integrate their respective digital pathology solutions, HALO AP and Galen; Sana Kliniken Berlin-Brandenburg (July 2021), to deploy an AI platform for cancer diagnostics; Roche (October 2021), to develop an embedded image analysis workflow for pathologists to access Ibex's AI algorithms; Dedalus Group (March 2022), to bring artificial intelligence (AI) to digital pathology; Hartford HealthCare (March 2022), to conduct a clinical research study using Ibex's AI-powered cancer diagnostics solution, Galen Breast; Source LDPath (December 2022), to deploy artificial intelligence (AI) technology in the entire pathology network at Source; AstraZeneca and Daiichi Sankyo (January 2023), to develop an AI-powered product that aids pathologists in accurately assessing HER2 immunohistochemistry (IHC) scoring in breast cancer patients; Alverno Laboratory (March 2023), to expand the deployment of Ibex’s Galen Suite of AI solutions to the entire Alverno network.

In October 2023 , the company partnered with Roche and Amazon to enable pathology laboratories to access Ibex’s tools through Roche’s Navify digital pathology software platform.

Funding and financials

In September 2023, the company raised USD 55 million in a Series C funding round led by 83North. The funds were used to expand Ibex's presence in the US and grow its product portfolio.